Key facts
- Juvenescence’s last known valuation is $502.0M (Aug 2019).
- It has raised $340.7M across 4 recorded rounds; the latest was Early Stage VC ($9.4M) in Dec 2020.
- Notable investors include Foresite Capital, London Technology Club, GG 1978, Grok Ventures, IDO Investments — 18 tracked in total.
- Juvenescence has filed 6 Form Ds with the SEC since 2017, most recently Jun 2021 ($9.4M sold to 15 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 18 names
- ·Watchlist + deal alerts for Juvenescence
Funding rounds
4 roundsAbout Juvenescence
Developer of an anti-aging therapeutics designed to extend healthy lifespan by targeting core aging mechanisms. The company leverages artificial intelligence to develop a pipeline of clinical and near-clinical stage candidates for cognition, cardio-metabolism, immunity, and cellular repair, enabling medical companies with the treatment and prevention of age-related diseases while supporting advancements in regenerative medicine.
- Sector
- Healthcare
- HQ
- Dublin, Ireland
- Founded
- 2016
- Employees
- 38
- Website
- juvlabs.com/
- Ownership
- Privately Held (backing)
Juvenescence doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Juvenescence shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Juvenescence in its N-PORT filings yet. We sweep new filings monthly.